SEC For	m 4																
FORM 4 UN			UNITED	ED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549										OMB APPROVAL			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			STAT		-	CHANGE to Section 16(a on 30(h) of the	_			_	-	HIP	Estim	Number ated ave per res	erage burde	3235-0287 n 0.5	
1. Name and Address of Reporting Person* LOSCALZO JOSEPH (Last) (First) (Middle)				2. Issuer Name and Ticker or Trading Symbol <u>LEAP THERAPEUTICS, INC.</u> [LPTX] 3. Date of Earliest Transaction (Month/Day/Year) 01/29/2024							elationship of Reporting Person(s) to Issuer eck all applicable) X Director 10% Owner Officer (give title Other (specify below) below)				wner		
C/O LEAP THERAPEUTICS, INC. 47 THORNDIKE STREET SUITE B1-1				4. If Amendment, Date of Original Filed (Month/Day/Year)) X Form f	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting					
(Street) CAMBRIDGE MA 02141				Rule 10b5-1(c) Transaction Indication													
(City) (State) (Zip)			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Tab	ole I - Nor	n-Deriv	ative Se	curities Ac	quired	, Disp	osed o	of, or Bei	neficiall	y Owned	1				
1. Title of Security (Instr. 3)				2. Transa Date (Month/E		Execution Date,		3. Transaction Code (Instr. 8)		ties Acquire d Of (D) (Inst	d (A) or r. 3, 4 and	5. Amou Securitie Benefici Owned F Reporte	es ally Following	Form:	nership Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code	v	Amount	(A) or (D)	Price	Transact (Instr. 3	tion(s)				
		-				urities Acq s, warrants						Owned					
1. Title of Derivative Security (Instr. 3)	. Title of 2. 3. Transaction 3A. Deeme Derivative Conversion Date Execution security or Exercise (Month/Day/Year) if any		Date, T	ransaction ode (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	Expiration Date of (Month/Day/Year) U			of Securities D Underlying S		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		

Date

1. The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024 for so long as the reporting person continues to be a director, consultant or service provider of the Company.

Exercisable

(1)

(D)

Expiration

01/29/2034

Date

/s/ Douglas E. Onsi as attorney-	01/21/2024
in fact for Joseph Losephzo	01/31/2024

Amount or Number

25,000

of Shares

Title

Common

Stock

in-fact for Joseph Loscalzo

\$<mark>0</mark>

25,000

D

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

01/29/2024

Stock Option (Right to Buy)

\$2.68

Explanation of Responses:

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code ۷

Α

(A)

25,000

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.